The company’s cash has increased to $43.9 million as of end-Dec 2020, compared to just $9.3m as of end-Jun 2020. Its total debts have declined to $11.3 million from $35.1 million, and is now in a net cash position of $32.6 million.
RHB Group Research’s Singapore Research team has maintained its “buy” call on UG Healthcare (UGHC), but lowered its target price from 95 cents to 75 cents on a new DCF methodology.
The team noted that UGHC recorded “satisfactory 1HFY21 results, and that 1HFY2021 core net profit surged 69 times to $54.9 million due to better average selling prices (ASP) and sales volume.
